| Size | Price | Stock | Qty |
|---|---|---|---|
| 50g |
|
||
| Other Sizes |
| Targets |
2,6-Dimethylphenylboronic acid is used as a reagent for the synthesis of orally bioavailable G Protein-Coupled Receptor 40 (GPR40) agonists for diabetes treatment. The compound does not have a defined pharmacological target of its own but serves as a building block for the synthesis of various pharmaceutical compounds, including antihistamines, antibiotics, and antiepileptics.
|
|---|---|
| ln Vitro |
It is employed as a reagent in self-coupling processes catalyzed by Pd, rhodium(I)-catalyzed 1,4-addition reactions, and Suzuki-Miyaura coupling reactions catalyzed by palladium. used in the synthesis of G protein-coupled receptors and protein kinase inhibitors.
In vitro, 2,6-dimethylphenylboronic acid is primarily used as a chemical reagent for organic synthesis. It serves as a key reagent in Suzuki coupling reactions, enabling the formation of carbon-carbon bonds essential for creating complex organic molecules. The compound is used in palladium-catalyzed Suzuki-Miyaura coupling reactions, Pd-catalyzed homocouplings, and rhodium(I)-catalyzed 1,4-addition reactions. |
| ln Vivo |
In vivo activity data for 2,6-dimethylphenylboronic acid itself are not available, as the compound is not intended for direct in vivo administration. Rather, it is a precursor used in the synthesis of drug candidates that are subsequently evaluated in animal models. The compound has a pharmacokinetic profile that allows it to be administered orally when incorporated into drug candidates.
|
| Enzyme Assay |
For in vitro chemical synthesis, 2,6-dimethylphenylboronic acid is used as a reagent for palladium-catalyzed Suzuki-Miyaura coupling reactions. Standard protocols involve reacting the boronic acid with an aryl halide in the presence of a palladium catalyst and a base in an appropriate solvent at elevated temperatures. The compound is also used in Pd-catalyzed homocouplings and rhodium(I)-catalyzed 1,4-addition reactions.
|
| Cell Assay |
For in vitro cell-based experiments, 2,6-dimethylphenylboronic acid is used as an intermediate in the synthesis of compounds that are tested in cell viability, proliferation, and cytotoxicity assays. The compound itself is not typically evaluated in cell-based assays. Standard cell culture protocols for test compounds synthesized from this intermediate involve dissolving the final product in DMSO and diluting to working concentrations.
|
| Animal Protocol |
In vivo animal studies using 2,6-dimethylphenylboronic acid are conducted on the final drug compounds synthesized from it, not on the intermediate itself. For GPR40 agonists for diabetes treatment derived from this building block, efficacy studies would typically be performed in mouse models of diabetes. Standard in vivo protocols involve oral administration to rodents, with measurement of blood glucose levels and pharmacokinetic parameters.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2,6-dimethylphenylboronic acid as a standalone compound are not characterized in the literature. The compound has a molecular weight of 149.98 g/mol, which is within the favorable range for oral bioavailability. The compound has a pharmacokinetic profile that allows it to be administered orally when incorporated into drug candidates. Empirical pharmacokinetic data are not available for this intermediate compound.
|
| Toxicity/Toxicokinetics |
2,6-Dimethylphenylboronic acid is a research chemical and should be handled with appropriate laboratory safety precautions. As a boronic acid derivative, it may cause skin and eye irritation. The compound should be stored under appropriate conditions. Specific LD₅₀ values, acute toxicity classifications, and chronic toxicity data are not available in the public literature. Standard safety practices include the use of personal protective equipment.
|
| Additional Infomation |
2,6-Dimethylphenylboronic acid (CAS 100379-00-8) is primarily a research-grade chemical intermediate, not an FDA-approved pharmaceutical drug. Its primary applications are as a reagent for palladium-catalyzed Suzuki-Miyaura coupling reactions. The compound is used in the synthesis of orally bioavailable GPR40 agonists for diabetes treatment and in the synthesis of antihistamines, antibiotics, and antiepileptics. No clinical trials or approved indications exist for this compound.
|
| Molecular Formula |
C8H11BO2
|
|---|---|
| Molecular Weight |
149.98
|
| Exact Mass |
150.085
|
| CAS # |
100379-00-8
|
| PubChem CID |
583322
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
299.9±50.0 °C at 760 mmHg
|
| Melting Point |
105 °C (dec.)(lit.)
|
| Flash Point |
135.2±30.1 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.523
|
| LogP |
2.51
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
11
|
| Complexity |
117
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])B(C1C(C([H])([H])[H])=C([H])C([H])=C([H])C=1C([H])([H])[H])O[H]
|
| InChi Key |
ZXDTWWZIHJEZOG-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H11BO2/c1-6-4-3-5-7(2)8(6)9(10)11/h3-5,10-11H,1-2H3
|
| Chemical Name |
(2,6-dimethylphenyl)boronic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.6676 mL | 33.3378 mL | 66.6756 mL | |
| 5 mM | 1.3335 mL | 6.6676 mL | 13.3351 mL | |
| 10 mM | 0.6668 mL | 3.3338 mL | 6.6676 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
